Nové trendy vo farmakoterapii II. (2011) - Jesseniova lekárska ...

JLF UK v Martine, 2011
5. Cooper C. The crippling consequences of
fractures and their impact on quality of life.
Am J Med 1997; 103 (Suppl 1): S12-S19.
6. Cummings SR, San Martin J, McClung MR,
Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB,
Austin M, Wang A, Kutilek S, Adami S, Zanchetta
J, Libanati C, Siddhanti S, Christiansen
C. Denosumab for prevention of fractures in
postmenopausal women with osteoporosis. N
Engl J Med. 2009; 361: 756-765.
7. Development Conference: Diagnosis, Prophylaxis
and Treatment of Osteoporosis. Am J
Med 1993; 94: 646–650.
8. Eghbali-Fatourechi G, Khosla S, Sanyal A,
Boyle WJ, Lacey DL, Giggs BL. Role of RANK ligand
in mediating increased bone resorption
in early postmenopausal women. J Clin Invest
2003; 111: 1221-1230.
9. Elliott R, Kostenuik P, Chen C. Denosumab is a
selective inhibitor of human receptor activator
of NF-Kb ligand (RANKL) that blocks osteoclast
formation and function. Osteoporos Int
2007; 18: S54. Abstract P149.
10. Hofbauer LC, Schoppet M. Clinical implications
of the osteoprotegerin/RANKL/RANK
system for bone and vascular diseases. JAMA
2004; 292: 490-495.
11. Kanis JA. Diagnosis of osteoporosis and assessment
of fracture risk. Lancet 2002; 359:1929-
1936.
12. Kanis JA, Johnell O, Oden A, Sernbo I, Redlund-Johnell
I, Dawson A, De Laet C, Jonsson
B. Long-term risk of osteoporotic fracture in
Malmo. Osteoporos Int 2000; 11: 669-674.
13. Kendler D, Roux C, Benhamou CL, Brown JP,
Lillestol M, Siddhanti S, Man HS, San Martin J,
Bone HG. Effects of denosumab on bone mineral
density and bone turnover in postmenopausal
women transitioning from alendronate
therapy. J Bone Miner Res 2010; 25(1):
72-81.
14. Kostenuik PJ, Stalhoub V. Osteoprotegerin a
physiological and pharmacological inhibitor of
bone resorption. Curr Pharm Des 2001; 7:
613-635.
15. Masaryk P. Epidemiológia osteoporózy, Via
Pract 2005; 11: 439-441.
16. Masaryk P, Letkovská A, Bitter K. Prevalence
of hip osteoporosis in Slovakia, Ann Rheum
Diss 1999; (Suppl. 1): 257.
17. Odborné usmernenie Ministerstva zdravotníctva
Slovenskej republiky pre diagnostiku a
liečbu osteoporózy. Vestník Ministerstva
zdravotníctva Slovenskej republiky 2006; ročník
54, čiastka 9-16.
18. Payer J, Killinger Z, Šulková I, Celec P. Therapeutic
adherence to bisphosphonates. Biomed
Pharmacother 2007; 61: 191-193.
19. Reginster JY, Burlet N. Osteoporosis: A still
increasing prevalence. Bone 2006; 38: S4-S9.
20. Simonet WS, Lacey DL, Dunstan CR, Kelley M,
Chang MS, Lüthy R, Nguyen2 HQ, Wooden S,
Bennett L, Boone T, Shimamoto G, DeRose M,
Elliott R, Colombero A, Tan HL, Trail G, Sullivan
J, Davy E, Bucay N, Renshaw-Gegg L, Hughes
TM, Hill D, Pattison W, Campbell P, Sander
S, Van G, Tarpley J, Derby P, Lee R, Boyle
WJ. Osteoprotegerin: A novel secreted protein
involved in the regulation of bone density.
Cell 1997; 89: 309-319.
21. Smith, MR, Egerdie B, Toriz NH, Feldman R,
Tammela TLJ, Saad F, Heracek J, j Szwedowski
M, Ke C, Kupic A, Leder BZ, Goessl C. Denosumab
in men receiving androgen-deprivation
therapy for prostate cancer. N Engl J Med
2009; 361: 745-755.
30